Opgen Inc (CFOR) — SEC Filings
Opgen Inc (CFOR) — 35 SEC filings. Latest: 8-K (Dec 23, 2025). Includes 23 8-K, 5 10-Q, 2 SC 13D/A.
Overview
Opgen Inc (CFOR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: On December 17, 2025, Opgen Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and changes in its board and officer composition, including compensatory arrangements. The filing details financial statements and exhibits related to t
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 8 bearish, 23 neutral, 4 mixed. The dominant filing sentiment for Opgen Inc is neutral.
Filing Type Overview
Opgen Inc (CFOR) has filed 23 8-K, 5 10-Q, 1 10-K, 1 10-Q/A, 2 SC 13D/A, 1 8-K/A, 1 DEF 14A, 1 SC 13D with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of CFOR's 34 recent filings, 11 were flagged as high-risk, 18 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $4,000,000 |
| Net Income | $2,493,129 |
| EPS | N/A |
| Debt-to-Equity | 0.24 |
| Cash Position | $414,211 |
| Operating Margin | 54.44% |
| Total Assets | $12,639,255 |
| Total Debt | $2,481,290 |
Key Executives
- David E. Lazar
Industry Context
OPGEN INC has undergone a significant strategic pivot from precision medicine to financial services and technology, specifically focusing on listing sponsorship services. This shift places it in a different competitive landscape, likely involving advisory firms and financial intermediaries. The industry trend towards specialized financial services and the increasing complexity of capital markets may create opportunities for companies offering such niche support.
Top Tags
corporate-governance (8) · material-agreement (6) · delisting (5) · equity-sale (4) · Strategic Pivot (4) · executive-compensation (4) · filing (4) · listing-standards (4) · financials (4) · amendment (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Report Date | 20251201 | The earliest event reported in the 8-K filing. |
| Filing Date | 20251205 | The date the 8-K report was filed with the SEC. |
| Total Revenue | $4,000,000 | for the nine months ended September 30, 2025, primarily from listing sponsorship services, up from $196,149 in 2024 |
| Net Income | $2,493,129 | for the nine months ended September 30, 2025, down from $7,642,696 in 2024 |
| Cash and Cash Equivalents | $414,211 | as of September 30, 2025, a decrease from $1,310,653 at December 31, 2024 |
| Accounts Receivable, net | $4,043,838 | as of September 30, 2025, a significant increase from $29,258 at December 31, 2024 |
| Operating Income | $2,177,744 | for the nine months ended September 30, 2025, a substantial improvement from an operating loss of $4,076,510 in 2024 |
| Common Stock Sale Right | $3.0 million | aggregate value of common stock OPGEN INC has the right to sell to AEI Capital Ltd. |
| Shares Outstanding | 10,071,286 | as of November 19, 2025 |
| General and Administrative Expenses | $1.1M | Decreased from $3.3M in prior year, reflecting scaled-down legacy operations. |
| Total Assets | $13.2M | Increased from $9.9M at December 31, 2024. |
| Total Stockholders' Equity | $10.7M | Increased from $7.4M at December 31, 2024. |
| Common Shares Outstanding | 10,071,286 | As of October 31, 2025. |
| Available Financing from AEI Capital Ltd. | $9.0M | Until December 31, 2025, providing liquidity runway. |
| Basic EPS | $0.31 | For the six months ended June 30, 2025, compared to $(0.98) in prior year. |
Forward-Looking Statements
- {"claim":"OpGen's stock price will face downward pressure due to dilution.","entity":"OPGN","targetDate":"Q1 2024","confidence":"high"}
- {"claim":"The company will use the proceeds for general corporate purposes and working capital.","entity":"OpGen, Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Opgen Inc (CFOR)?
Opgen Inc has 35 recent SEC filings from Jan 2024 to Dec 2025, including 23 8-K, 5 10-Q, 2 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CFOR filings?
Across 35 filings, the sentiment breakdown is: 8 bearish, 23 neutral, 4 mixed. The dominant sentiment is neutral.
Where can I find Opgen Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Opgen Inc (CFOR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Opgen Inc?
Key financial highlights from Opgen Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CFOR?
The investment thesis for CFOR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Opgen Inc?
Key executives identified across Opgen Inc's filings include David E. Lazar.
What are the main risk factors for Opgen Inc stock?
Of CFOR's 34 assessed filings, 11 were flagged high-risk, 18 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Opgen Inc?
Recent forward-looking statements from Opgen Inc include guidance on {"claim":"OpGen's stock price will face downward pressure due to dilution.","entity":"OPGN","targetDate":"Q1 2024","conf and 1 other predictions.